Xanomeline-Trospium for Adults with Schizophrenia Experiencing Acute Psychosis: A Systematic Review and Meta-analysis of Safety and Tolerability Outcomes

Abstract

The United States Food and Drug Administration approved the xanomeline-trospium combination in September 2024 for treating schizophrenia, based in part on three double-blind, randomized placebo-controlled trials in adults with schizophrenia experiencing acute psychosis. This random-effects model pairwise meta-analysis of those three trials found that xanomeline-trospium was comparable to placebo in terms of all-cause discontinuation, discontinuation rate due to adverse events, Simpson–Angus Scale score change, Barnes Akathisia Rating Scale score change, body weight change, body mass index change, blood pressure change, serum total cholesterol change, blood glucose change, QTc interval changes, and the incidence of headache, somnolence, insomnia, dizziness, akathisia, agitation, tachycardia, gastroesophageal reflux disease, diarrhea, increased weight, and decreased appetite. However, xanomeline-trospium was associated with a higher incidence of at least one adverse event, dry mouth, hypertension, nausea, vomiting, dyspepsia, and constipation, and increased serum triglyceride compared with placebo. Notably, xanomeline-trospium demonstrated superior efficacy than placebo in improving the Positive and Negative Syndrome Scale (PANSS) total score, PANSS positive subscale score, and PANSS negative subscale score.

Keywords

xanomeline-trospium - KarXT - schizophrenia experiencing acute psychosis - efficacy and safety - systematic review and meta-analysis

Publication History

Received: 17 October 2024
Received: 08 December 2024

Accepted: 10 December 2024

Article published online:
29 January 2025

• References

• 1 Solmi M, Seitidis G, Mavridis D. et al. Incidence, prevalence, and global burden of schizophrenia – data, with critical appraisal, from the Global Burden of Disease (GBD) 2019. Mol Psychiatry 2023;
• 2 Wolf G, Singh S, Blakolmer K. et al. Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale and strategy for safe implementation. Mol Psychiatry 2023; 28: 44-58
• 3 Correll C, Citrome L. Pharmacologic treatment of schizophrenia beyond dopamine receptor blockade-Has its time come yet?. JAMA Psychiatry 2024; 1: 118-120
• 4 FDA. U.S. Food and Drug Administration. Date of last search: 16/04/2024
• 5 Paul SM, Yohn SE, Popiolek M. et al. Muscarinic acetylcholine receptor agonists as novel treatments for schizophrenia. Am J Psychiatry 2022; 179: 611-627
• 6 Brannan SK, Sawchak S, Miller AC. et al. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med 2021; 384: 717-726
• 7 Kaul I, Sawchak S, Correll CU. et al. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. Lancet 2024; 403: 160-170
• 8 Kaul I, Sawchak S, Walling DP. et al. Efficacy and safety of xanomeline-trospium chloride in schizophrenia: A randomized clinical trial. JAMA Psychiatry 2024; 81: 749-756
• 9 Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276
• 10 Huhn M, Nikolakopoulou A, Schneider-Thoma J. et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis. Lancet 2019; 394: 939-951
• 11 Citrome L, Neugebauer N, Meli A. et al. KarXT (xanomeline and trospium) for the treatment of schizophrenia: Number needed to treat, number needed to harm, and likelihood to be helped or harmed. ASCP Annual Meeting, May 28–31, Miami Beach, Florida. 2024
• 12 Brannan S, Cutler A, Sawchak S. et al. Safety and tolerability of KarXT (xanomeline–trospium): Pooled results from the randomized, double-blind, placebo-controlled EMERGENT Trials. NEI Congress, November 9–12, 2023, Colorado Springs, Colorado. 2023
• 13 Kaul I, Sawchak S, Claxton A, Sauder C, Hassman HH, Kakar R, Walling DP, Citrome L, Zhu H, Miller AC, Brannan SK. Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials. Schizophrenia (Heidelb). 2024; 10: 102
• 14 Wright AC, McKenna A, Tice JA. et al. A network meta-analysis of KarXT and commonly used pharmacological interventions for schizophrenia. Schizophr Res 2024; 274: 212-219
• 15 Page MJ, McKenzie JE, Bossuyt PM. et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021; 372: n71
• 16 Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672-676
• 17 Cochrane. http://tech.cochrane.org/Revman version 54 for Windows.
• 18 DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188
• 19 Higgins J, Thomas J, Chandler J. et al. Cochrane handbook for systematic reviews of interventions version 6.2. wwwtrainingcochraneorg/handbook 2021
• 20 Citrome L, Nasrallah HA. On-label on the table: What the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not. Expert Opin Pharmacother 2012; 13: 1599-1613